FULGENT GENETICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Fulgent Genetics, Inc.
New Orleans, Sept. 27, 2022 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 21, 2022 to file lead plaintiff applications in a securities class action lawsuit against Fulgent Genetics, Inc. (NasdaqGM: FLGT), if they purchased the Company’s securities between March 22, 2019 and August 4, 2022, inclusive.
What is the class action lawsuit about?
The lawsuit alleges that Fulgent Genetics, Inc. made materially false and/or misleading statements and failed to disclose that the Company’s testing volumes had declined, which negatively impacted its revenues, and that Fulgent’s positive statements about its business, operations, and prospects were materially misleading and lacked a reasonable basis. As a result of this information being withheld from investors, the price of Fulgent Genetics, Inc. stock was artificially inflated during the class period.
Investors who suffered losses in excess of $100,000 are encouraged to contact ClaimsFiler before the November 21, 2022 lead plaintiff deadline to learn more about their rights and potential recovery.
Impact on Investors:
Investors who purchased Fulgent Genetics, Inc. securities between March 22, 2019 and August 4, 2022 may be eligible to participate in a securities class action lawsuit seeking to recover losses on their investments. By filing a lead plaintiff application before the deadline, investors can take an active role in seeking to recover any losses sustained as a result of alleged securities fraud.
How will this affect me?
If you are an investor who purchased Fulgent Genetics, Inc. securities during the specified period and suffered losses, you may have the opportunity to participate in the class action lawsuit against the company. By filing a lead plaintiff application, you can seek to recover any losses you incurred as a result of the alleged securities fraud committed by Fulgent Genetics, Inc.
How will this affect the world?
Class action lawsuits against companies like Fulgent Genetics, Inc. can have broader implications for the financial markets and investor confidence. When companies are held accountable for fraudulent or misleading practices, it can help to promote transparency and integrity in the financial sector. By bringing attention to these issues and seeking justice for investors who have been harmed, class action lawsuits play a role in holding corporations responsible for their actions and maintaining trust in the market.
Conclusion:
As the deadline for lead plaintiff applications in the class action lawsuit against Fulgent Genetics, Inc. approaches, investors who suffered losses in excess of $100,000 during the specified period should consider taking action to protect their rights and potentially recover their losses. By participating in the lawsuit, investors can play a part in seeking accountability for alleged securities fraud and promoting fairness and transparency in the financial markets.
